Vergelijking

Glepaglutide vs. Terlipressin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

geen gegevens

14636-12-5

Molecuulmassa

geen gegevens

1227.37 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Terlipressin

Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Glepaglutide	Terlipressin
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Glepaglutide

Volledige vermelding →

Terlipressin

Volledige vermelding →

Frequently asked questions

What is the difference between Glepaglutide and Terlipressin?: Glepaglutide is classified as "Onderzoek (overig)", while Terlipressin is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Terlipressin?: The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Terlipressin in Germany and the United States?: Duitsland: Glepaglutide — Niet goedgekeurd, Terlipressin — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Terlipressin — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Terlipressin

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Glepaglutide and Terlipressin?

Glepaglutide is classified as "Onderzoek (overig)", while Terlipressin is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Terlipressin?

The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Terlipressin in Germany and the United States?

Duitsland: Glepaglutide — Niet goedgekeurd, Terlipressin — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Terlipressin — Op recept. These are factual summaries with source and review date on the individual pages.